Phase I study to evaluate the tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) of PM01183 (Lurbinectedin) in combination with olaparib in patients with advanced solid tumors

Category Primary study
JournalJournal of Clinical Oncology
Year 2017
This article has no abstract
Epistemonikos ID: f434dd25be9a7fba77f1f4625518b44daef8abad
First added on: Feb 08, 2025